Kidney disease screening outreach: CKD testing for patients at risk, the USPSTF update in progress, Medicare coverage and private reminders

Chronic kidney disease (CKD) screening is a blood test and a urine test for people at higher risk, read by a clinician and repeated when needed. Federal health agencies say early kidney disease can go unnoticed, which makes outreach worth doing and easy to do badly. A page can frighten the reader with a statistic, promise that a test will catch every problem, sell a home kit as a kidney checkup, call the test free with no conditions, or treat one lab result as a diagnosis. A reminder can tell a spouse or a roommate about a lab result the patient has not discussed with anyone. This guide covers how a primary care practice, a community health center, a diabetes or blood pressure program, an endocrinology practice or a nephrology practice can invite patients at risk to kidney testing on the federal sources as written, say plainly that the USPSTF has no current recommendation on screening, keep testing apart from diagnosis and from coverage, and write calm, private pages and messages.

Ten related topics have their own guides and are not repeated here. The practices that test are covered in our guides to primary care practice marketing, community health center marketing and endocrinology practice marketing. The programs for people at risk are covered in our guides to diabetes education program marketing and hypertension program marketing. Care after a positive test is covered in our guides to nephrology practice marketing, chronic care management marketing and dialysis center marketing. The outreach that sits next to it is covered in our guides to annual wellness visit outreach and diabetic eye exam outreach.

What the federal sources say

The USPSTF rates screening, CDC and NIDDK describe who is at risk and which tests are used, MedlinePlus explains the condition to patients, and CMS sets Medicare coverage. The points that shape kidney screening outreach:

• The USPSTF topic page Chronic Kidney Disease: Screening (checked October 30, 2026) is marked inactive. It says the recommendation is out of date, that the Task Force is reviewing the evidence and updating its recommendations, that the previous evidence review and recommendation issued in 2012 may contain information that is outdated, and that it encourages primary care clinicians to consult other sources for current evidence while the topic is updated. The final research plan for the update is dated July 13, 2023, and covers adults 18 and older.
• The CDC page Screening for Chronic Kidney Disease (September 17, 2025, read through an archived copy) tells health care providers to focus screening on high-risk patients, such as those with high blood pressure, diabetes and cardiovascular disease, and names a family history of kidney disease and a history of acute kidney injury as key risk factors. It says simple blood and urine tests can find the disease in its early stages.
• The CDC page Chronic Kidney Disease Basics (May 15, 2024, read through an archived copy) says that more than 1 in 7 American adults has chronic kidney disease (CKD) and that up to 9 in 10 of them do not know they have it, and that people with CKD may not feel ill or notice any symptoms. The CDC page Risk Factors for Chronic Kidney Disease (May 14, 2024) names diabetes, high blood pressure, heart disease, a family history of CKD and obesity.
• The CDC page Testing for Chronic Kidney Disease (May 15, 2024) describes urine tests for albumin, including a test that compares albumin with creatinine, and a blood test for creatinine used to estimate kidney function. It says a urine albumin result of 30 or above may mean kidney disease and that the test may be repeated once or twice to confirm the results.
• The NIDDK page Chronic Kidney Disease Tests and Diagnosis (last reviewed October 2016, an older page) says testing is the only way to know how well the kidneys are working, tells people with diabetes to get checked every year, and tells people with high blood pressure, heart disease or a family history of kidney failure to talk with their provider about when to be tested. The NIDDK page Causes of Chronic Kidney Disease (last reviewed February 2025) names diabetes and high blood pressure as leading causes.
• The MedlinePlus page Chronic Kidney Disease (last updated September 21, 2025) says blood and urine tests are the only way to know if you have kidney disease.
• The Medicare.gov page Diagnostic laboratory tests (checked October 30, 2026) says Part B covers medically necessary diagnostic laboratory tests when a health care provider orders them. The Medicare.gov page Kidney disease education says Part B covers up to 6 sessions for a person with Stage 4 chronic kidney disease who is referred by a doctor or other qualified provider, with the Part B deductible and coinsurance applying.

We checked for changes before writing. On October 30, 2026, the USPSTF search listed the screening topic as in progress, with the 2012 recommendation marked inactive and no draft recommendation posted; we found no draft or final update. The CDC pages cited here were read through archived copies, since the CDC site did not answer our direct requests, and we could not confirm developments after those dates. Two NIDDK pages carry a last reviewed date of October 2016, which we note next to each one. A practice page should quote the sources in force on the day it is written, say that the USPSTF update is in progress if it still is, and record that date in its review notes.

The Task Force itself has changed. In Kennedy v. Braidwood Management, decided June 27, 2025, the Supreme Court held that Task Force members are inferior officers whose appointment by the Secretary of HHS is consistent with the Appointments Clause. On September 17, 2026, HHS announced eight new members who join the eight already serving. The kidney screening update was planned before that change, so check the USPSTF page again before a campaign runs.

Two points shape the marketing. First, the USPSTF has no current recommendation on CKD screening: its 2012 recommendation is marked inactive and the update is in progress. A page should not say the Task Force recommends kidney screening for everyone, or for anyone; it can quote CDC and NIDDK, which tell providers and patients at risk to test, with their dates. Second, a screening result is not a diagnosis: CDC says the urine test may be repeated to confirm the result, and the clinician reads the results with the patient’s history. A page that turns one number into a verdict overstates the test.

Kidney screening pages and claims that need rewriting

Google’s search suggestions, which we checked on October 30, 2026, offer “kidney screening test”, “kidney screening near me”, “kidney screening blood test” and “kidney screening test price” to a person who types “kidney screening”, and “ckd screening guidelines”, “ckd screening tests” and “ckd screening uspstf” to a person who types “ckd screening”. For “kidney test near me” they offer “kidney function test near me” and “free kidney test near me”, and for “kidney disease screening” they offer “kidney disease test at home” and “kidney disease test results”. For “does medicare cover kidney” they offer “does medicare cover kidney disease”. Suggestions with code terms belong to the billing staff, not the patient page. The pattern is clear: people want to know what the tests are, where to get them, what they cost, whether a home test is enough and what the results mean.

A page that holds up names the two tests in plain words, says who CDC and NIDDK say should be tested, says the USPSTF update is in progress, says the clinician explains the results and may repeat a test before reaching a diagnosis, states coverage with its conditions, keeps home kits and supplements out of the offer, and offers the page in the languages the practice’s patients speak.

Phrases that need rewriting:

• “9 in 10 people with kidney disease don’t know it. Are you one of them?” A statistic used to alarm, with no date or source. Quote CDC by name and date if the page uses the figure, and pair it with what the reader can do: ask about testing if they have a risk factor.
• “The USPSTF recommends kidney screening.” The USPSTF marks its 2012 recommendation as inactive and lists the update as in progress. Say so, and build the page on the CDC and NIDDK pages instead.
• “Our kidney panel catches kidney disease before it starts.” A promise with no source. Say the blood and urine tests can find kidney disease in its early stages, as CDC says, and that the clinician explains what the results mean.
• “One test and you’ll know for sure.” CDC says the urine test may be repeated once or twice to confirm the results. Say the clinician may repeat a test before reaching a diagnosis.
• “Reverse kidney damage with our program.” A treatment promise with no source. Say the practice offers testing, follow-up and referral to a kidney specialist where needed, and name no medicine.
• “Free kidney screening.” Coverage depends on the payer, the plan and the reason for the test. State the conditions, or say the practice checks coverage first.
• “Skip the doctor: test your kidneys at home.” The FDA Home Use Tests page says home tests should not replace periodic visits to a doctor. Do not sell a home kit as a substitute for testing ordered and read by a clinician.
• “We’ve found kidney disease in hundreds of patients.” Numbers with no source. Remove them unless they come from the practice’s own documented and reviewed records, with their date and limits stated.

Under 15 U.S.C. 45, deceptive acts or practices in commerce are unlawful, and 15 U.S.C. 52 prohibits false advertisements likely to induce the purchase of drugs, devices, services or cosmetics. The FTC staff Health Products Compliance Guidance says claims about the health benefits or safety of health-related products require competent and reliable scientific evidence, and that an advertiser is responsible for the claims its ads convey, including implied ones. Quoting the federal sources as written, with each one named and dated, stays inside that standard; turning a federal statement into a promise to a patient does not.

Symptoms, results questions and 911 in every tool

A kidney screening page invites people who feel well to be tested. It also reaches people with symptoms and people reading a lab result on their own. Put one plain line on the page, on flyers, in reminders and in the footer of the booking page: if you have a medical emergency, call 911. Questions about symptoms or about a result go to the care team, not to a booking form.

The same wording belongs in voicemail, after-hours greetings, portal replies, text replies, chat and AI front desk tools. A tool should send any message describing an emergency to 911 at once and alert staff, route questions about symptoms or a result to a clinician, and never tell a person what a lab number means, whether they have kidney disease or whether to change a medicine. Our guides to the AI chatbot on a practice website and answering service versus AI receptionist cover how tools hand off these messages.

Who to invite: diabetes, blood pressure, heart disease and family history

Patients come to kidney testing from different programs, and each group needs its own wording.

Keep these points:

• Adults with diabetes: NIDDK tells people with diabetes to get checked every year, and CDC names diabetes among the high-risk groups. Invite them through the diabetes visit or a yearly lab order, in the practice’s own protocol.
• Adults with high blood pressure or heart disease: CDC names both as risk factors, and NIDDK tells these patients to talk with their provider about when to be tested. Invite them to that conversation, not to a test they have not discussed.
• A family history of kidney disease or a past acute kidney injury: CDC names both as key risk factors. A page can ask readers who have either to mention it at their next visit.
• People who already have a CKD diagnosis: they need follow-up and management, not a screening slot. Point them to the practice’s kidney care or to a nephrology practice.
• Children and pregnancy: the USPSTF research plan covers adults and excludes pregnant persons. Leave testing in children and in pregnancy to the clinician and the practice’s own protocol, and do not market kidney screening to parents as a test of a child.
• Public ads: invite by risk factor the reader knows about themselves, such as diabetes or high blood pressure, and do not single out a group by background, neighborhood or language.

Our guides to diabetes prevention program marketing, hypertension program marketing and marketing to Medicare patients cover the wider rules for those pages.

After the test: results, repeat tests and referral

A result leads to a conversation, not a label. CDC says the urine test may be repeated once or twice to confirm the results, and NIDDK says the same two tests are used to monitor kidney disease once it is found. A page should describe the next steps in plain words and in the practice’s own terms: who explains the results, how the patient hears about them, whether a repeat test is ordered, and that the patient decides with the clinician what comes next.

Some patients need a kidney specialist. The page can say the practice refers patients to nephrology when the clinician judges it needed, and that patients can choose among specialists where more than one is available. For patients with Stage 4 CKD, Medicare.gov describes up to 6 kidney disease education sessions with a referral. Do not name medicines, diets sold as treatment or treatment courses on a marketing page, and do not promise to slow, stop or reverse kidney disease; treatment choices belong to the clinician and the patient. The NIDDK page Managing Chronic Kidney Disease (last reviewed October 2016) tells patients to talk with their provider about every medicine, vitamin and supplement they take. Our guides to nephrology practice marketing and chronic care management marketing cover those services.

Coverage: preventive rules, Medicare and free screening days

Under 42 U.S.C. 300gg-13, group health plans and health insurers must cover, without cost sharing, services with a USPSTF A or B rating in effect. CKD screening has no current USPSTF rating: the 2012 recommendation is marked inactive and the update is in progress. So that rule does not by itself make kidney testing free, and whether a plan covers it depends on the plan and the reason the test is ordered. Medicare coverage follows the Medicare.gov rules above for diagnostic laboratory tests ordered by a provider, and Medicaid coverage is set state by state. Keep the recommendation and the coverage apart on the page, say the practice checks coverage before the visit, and do not write “free under the ACA”. Cash prices follow our guides to advertising cash prices and good faith estimates for self-pay patients.

A free screening day at a church, a workplace or a community event, or a gift for coming in, follows 16 CFR 251.1, which says a free offer must not be recouped through a raised price or a reduced quantity or quality elsewhere, and that the terms of the offer should be stated at the outset. Under 42 U.S.C. 1320a-7a(a)(5), civil penalties can apply to a person who offers or transfers remuneration to a Medicare or state health care program beneficiary that the person knows or should know is likely to influence the beneficiary to order or receive items or services from a particular provider, practitioner or supplier. A gift card for coming in needs counsel’s review before it runs. A screening event also needs a private place to collect samples and share results, a plan for who calls a person whose result needs follow-up, and the 911 line on its materials. Our guide to health fair and screening event marketing covers event rules.

Home kits, supplements and products sold alongside

People search for home kidney tests, and a practice may be offered home kits, kidney supplements or detox products to sell next to its screening program. The FDA page Home Use Tests (content current as of June 21, 2022, an older page) says home tests are intended to help with health care but should not replace periodic visits to a doctor, and that tests are best evaluated together with a medical history, a physical exam and other testing. The FDA Questions and Answers on Dietary Supplements (content current as of August 27, 2026) says FDA does not have the authority to approve dietary supplements before they are marketed. Name no product, make no claim that a supplement, a cleanse or a food protects or repairs the kidneys, and follow our guides to selling supplements in a medical practice and direct-to-consumer lab testing marketing.

Recall texts, letters and reminders

Kidney testing reaches patients through visit and lab reminders: a diabetes visit, a yearly lab order, an annual wellness visit or a repeat test. Under 45 CFR 164.501, a communication about the practice’s own treatment for an individual, such as a reminder to come in for a recommended service, can fall outside the definition of marketing, while a message that promotes a third party’s product or service generally needs a signed authorization under 45 CFR 164.508.

The words in the message matter as much as the rule. A text, a postcard or a voicemail can be seen by a spouse, a parent, a roommate or an employer. Keep these points:

• Invite to the visit or the lab, not to the topic: “[Practice name]: you are due for a visit and lab work. Call [phone] or reply to book.” A reminder for a repeat test should not say why it was ordered.
• Never put kidney disease, a lab value, a result or a diagnosis in a text, a postcard, a voicemail or an email subject line; share results through the portal or a call, as the practice’s protocol says.
• Use the contact method and number the patient chose, and keep the caller ID and the sender name neutral.
• For a minor, follow the practice’s protocol and 45 CFR 164.502(g), which defers to state and other law on when a parent acts as a minor’s personal representative.
• Give every message an easy opt-out, and honor it.

Our guides to text message appointment reminders and the patient recall system cover consent, timing and opt-outs.

Families and caregivers

Relatives book visits and drive patients to the lab, and a spouse or an adult child may call to ask about a result. Under 45 CFR 164.510(b), a covered entity may share information relevant to a family member’s or friend’s involvement in a patient’s care when the patient agrees or does not object, or, when the patient is not present or cannot agree, when the professional judges it is in the patient’s best interest. The intake team should ask the patient what may be shared and with whom, and record it. CDC says CKD runs in families, so a page can suggest that a patient tell relatives about a family history of kidney disease; the practice itself should not contact relatives about a patient’s result.

Labs, partners and referral payments

Under 42 U.S.C. 1320a-7b(b), the federal anti-kickback statute, it is a crime to knowingly and willfully offer, pay, solicit or receive any remuneration to induce or reward referrals of items or services payable by a federal health care program. Under 18 U.S.C. 220, it is also a crime to knowingly and willfully solicit, receive, offer or pay remuneration for referrals to a laboratory, with respect to services covered by a health care benefit program. Rules on referral fees are also set state by state.

For a kidney screening program, keep these points:

• Do not accept payment from a lab, a dialysis organization, a specialist or a product maker for the patients the practice sends them, and do not pay a church, an employer or a community group per person screened or referred, without counsel’s review.
• A lab that offers free collection staff, free kits or marketing help for a screening day needs counsel’s review before the practice accepts it; our guide to clinical lab marketing to physicians covers the lab side.
• Give patients more than one specialist or dialysis option where they exist, and tell them they can choose; our guide to patient and physician referrals covers referral rules.

Privacy, pixels and ads

A lab booking, a result page in the portal or a page about kidney disease can say something sensitive about a person’s health. Keep form answers, bookings and page clicks out of tracking pixels and ad platform tools unless a written agreement covers them; our guide to tracking pixels on practice websites covers the setup. The Google Ads personalized advertising policy lists health among its sensitive interest categories and restricts targeting based on it. Ads can target by place, language settings and search terms such as “kidney screening near me”, and should not be built from a list of patients with diabetes, high blood pressure or an abnormal kidney result taken from the practice’s records. Ad copy should not address the reader as a person who has kidney disease.

Tone, access and patient stories

Kidney disease can frighten people, and a person who feels alarmed may avoid the test rather than book it. Present testing as routine care for people with a risk factor, use calm words, and keep out alarm: no images of dialysis machines in a screening ad, no countdowns to kidney failure, no wording that blames the reader for a condition. Write in plain words, offer the page in the languages the practice’s patients speak, and link the translated versions of federal pages where they exist; NIDDK and MedlinePlus offer kidney pages in Spanish. The Department of Justice Guidance on Web Accessibility and the ADA describes website features such as text alternatives, enough color contrast and the ability to resize text that help people with disabilities use a site; our guide to Spanish language medical marketing covers translation.

A patient’s story about finding kidney disease early can help others. Under 16 CFR 255.2, an ad that shows one person’s result on a key attribute is likely to be read as what others will generally achieve, unless the advertiser has substantiation for that or clearly and conspicuously discloses what people can generally expect. Use a story only if the patient chose to share it in writing, get a signed authorization under 45 CFR 164.508 where the practice is a covered entity, leave out lab values the patient did not choose to share, say if the patient received anything for taking part, let them review the final version, and let them withdraw it later. Our guides to patient photo consent and testimonials and before and after photos cover the full rules.

Illustration: two kidney screening messages

Illustration: a flyer reads “9 in 10 people with kidney disease don’t know it. Don’t end up on dialysis! The USPSTF recommends kidney screening, and our free kidney panel catches it before it starts. Can’t make it in? Order our home kit and kidney cleanse. Hundreds of patients diagnosed here.” It uses a statistic to frighten with no source or date, misstates the USPSTF position, promises a result, makes a free claim with no conditions, sells a home kit and a supplement in place of care, gives no emergency line, and uses numbers with no source.

Illustration: a second flyer for the same practice reads “At [Practice name], we offer kidney testing to patients with diabetes, high blood pressure, heart disease or a family history of kidney disease, as CDC advises. It is a blood test and a urine test, and your clinician explains the results with you and may repeat a test before reaching a diagnosis. We check your coverage first. If you have a medical emergency, call 911. To book, call [phone], [days and hours].” It quotes the source, describes the tests plainly, keeps the result apart from the diagnosis, states that coverage is checked and gives the emergency line.

Checklist before a kidney screening campaign goes live

• Copy built on the CDC, NIDDK, MedlinePlus and Medicare.gov pages, each named and dated, with older pages marked as older; the USPSTF topic described as inactive with an update in progress; the sources checked again on the day the page is written, with the date recorded.
• Any statistic quoted with its source and date and paired with a next step; no alarm, no dialysis images in screening ads, no wording that blames the reader.
• Testing kept apart from diagnosis, with repeat tests and the clinician’s reading described; no promises to catch, slow, stop or reverse kidney disease and no medicine names.
• The 911 line on pages, flyers, voicemail, after-hours greetings, portal replies, text replies, chat and AI front desk tools; symptom and result questions routed to a clinician.
• Invitations by risk factor as CDC and NIDDK describe them; people with a diagnosis sent to kidney care; children and pregnancy left to the clinician’s protocol.
• Coverage described as 42 U.S.C. 300gg-13 and Medicare.gov state it, with plan coverage checked per patient; free screening days and gifts reviewed under 16 CFR 251.1 and 42 U.S.C. 1320a-7a(a)(5).
• Reminders, postcards, caller ID names, voicemails and subject lines carry no mention of kidneys, lab values or results.
• Family requests handled under the patient’s recorded wishes; no contact with relatives about a patient’s result.
• No home kit, cleanse or supplement claims and no brand names; no payments to or from labs, dialysis organizations, specialists or community partners without counsel’s review under the anti-kickback statute and 18 U.S.C. 220; patient stories with signed authorizations.
• Patient lists and results stay out of ad audiences and tracking tools; the page offered in the languages the practice’s patients speak and checked against the ADA web guidance.

How we help

We build websites, local search, Google Ads and AI front desk tools for independent practices and health businesses, including primary care practices, community health centers, endocrinology practices and nephrology practices. For a kidney screening program, that means a site that builds its pages on the CDC, NIDDK and Medicare.gov pages as written and dated, says plainly that the USPSTF update is in progress, keeps testing apart from diagnosis and both apart from coverage, and answers “kidney screening near me” and “kidney function test” searches calmly and honestly, plus appointment request pages that book a visit or a lab without asking about lab values on the web and keep answers away from tracking tools. Our front desk tools send any message about an emergency to 911 and alert staff, route symptom and result questions to a clinician, and do not tell anyone what a lab number means. We do not decide who should be tested or treated; your clinicians and patients do. Our tools are built with HIPAA in mind. We confirm in writing what a BAA covers before any patient information flows through a tool, and if it is not covered, we do not route patient information through it. We are not a healthcare provider and we do not give legal or medical advice. We do not sell lead lists and we do not pay for referrals. For the wider rules, see our healthcare marketing rules hub.

Sources

• USPSTF: Inactive: Chronic Kidney Disease: Screening (checked October 30, 2026)
• USPSTF: Final Research Plan: Chronic Kidney Disease: Screening (July 13, 2023)
• USPSTF: Recommendations in progress (checked October 30, 2026)
• HHS: Secretary Kennedy Announces New Appointments to U.S. Preventive Services Task Force (September 17, 2026)
• Kennedy v. Braidwood Management, Inc. (U.S. Supreme Court, decided June 27, 2025)
• CDC: Screening for Chronic Kidney Disease (September 17, 2025)
• CDC: Chronic Kidney Disease Basics (May 15, 2024)
• CDC: Testing for Chronic Kidney Disease (May 15, 2024)
• CDC: Risk Factors for Chronic Kidney Disease (May 14, 2024)
• NIDDK: Chronic Kidney Disease Tests and Diagnosis (last reviewed October 2016)
• NIDDK: Causes of Chronic Kidney Disease (last reviewed February 2025)
• NIDDK: Managing Chronic Kidney Disease (last reviewed October 2016)
• MedlinePlus: Chronic Kidney Disease (last updated September 21, 2025)
• Medicare.gov: Diagnostic laboratory tests (checked October 30, 2026)
• Medicare.gov: Kidney disease education (checked October 30, 2026)
• FDA: Home Use Tests (content current as of June 21, 2022)
• FDA: Questions and Answers on Dietary Supplements (content current as of August 27, 2026)
• 42 U.S.C. 300gg-13: Coverage of preventive health services
• 45 CFR 164.501: Definitions
• 45 CFR 164.502: Uses and disclosures of protected health information: General rules
• 45 CFR 164.508: Uses and disclosures for which an authorization is required
• 45 CFR 164.510: Uses and disclosures requiring an opportunity for the individual to agree or to object
• 15 U.S.C. 45: Unfair methods of competition unlawful
• 15 U.S.C. 52: Dissemination of false advertisements
• FTC: Health Products Compliance Guidance (December 2022)
• 16 CFR 251.1: Guide concerning use of the word free and similar representations
• 42 U.S.C. 1320a-7a: Civil monetary penalties
• 42 U.S.C. 1320a-7b: Criminal penalties for acts involving Federal health care programs
• 18 U.S.C. 220: Illegal remunerations for referrals to recovery homes, clinical treatment facilities, and laboratories
• 16 CFR 255.2: Consumer endorsements
• Google Ads: Personalized advertising policy
• U.S. Department of Justice: Guidance on Web Accessibility and the ADA

More in Physician specialty marketing